VYNE
NASDAQ · Pharmaceuticals
Vyne Therapeutics Inc
$0.65
+0.00 (+0.00%)
Financial Highlights (FY 2026)
Revenue
444.0K
Net Income
-20,672,061
Gross Margin
93.4%
Profit Margin
-4,646.1%
Rev Growth
+5.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 93.4% | 93.4% | 36.5% | 36.5% |
| Operating Margin | -5,219.1% | -4,697.2% | 24.1% | 26.2% |
| Profit Margin | -4,646.1% | -4,413.8% | 22.3% | 17.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 444.0K | 419.3K | 2.72M | 3.05M |
| Gross Profit | 414.6K | 391.5K | 990.9K | 1.11M |
| Operating Income | -23,173,988 | -19,694,607 | 655.4K | 797.6K |
| Net Income | -20,672,061 | -17,568,323 | 604.8K | 522.0K |
| Gross Margin | 93.4% | 93.4% | 36.5% | 36.5% |
| Operating Margin | -5,219.1% | -4,697.2% | 24.1% | 26.2% |
| Profit Margin | -4,646.1% | -4,413.8% | 22.3% | 17.1% |
| Rev Growth | +5.9% | +5.9% | -5.6% | +23.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 5.81M | 7.24M |
| Total Equity | — | — | 10.77M | 11.64M |
| D/E Ratio | — | — | 0.54 | 0.62 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -23,205,991 | -20,817,461 | 831.2K | 1.01M |
| Free Cash Flow | — | — | 485.0K | 536.6K |